Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space
May 25 2022 - 8:30AM
via InvestorWire —
Lexaria Bioscience Corp. (NASDAQ:
LEXX) today announces its placement in an editorial
published by NetworkNewsWire ("NNW"), one of 50+ trusted brands
within the InvestorBrandNetwork (“IBN”), a multifaceted financial
news and publishing company for private and public entities.
To view the full publication, “Nicotine Surges as Smoking Sags,”
please visit: https://nnw.fm/WNblw
Seems like yesterday people were smoking cigarettes everywhere;
many people still have memories of Grandpa puffing on his Camels.
It wasn’t until 1993 that smoking was banned in hospitals and on
airplanes in 1998. Despite these and many other restrictions, the
global market for nicotine-based products remains incredibly
robust. Total global retail sales associated with the nicotine
ecosystem during 2020 reached approximately $853 billion with
around 5.2 trillion retail cigarette sticks sold. Nicotine isn’t
just big business, it’s huge business, and companies are constantly
looking for ways to keep and grow market share.
The majors are evermore turning to innovation and alternative
delivery methods to achieve their objectives. An example of that is
the breakthrough technology of Lexaria Bioscience Corp.
(NASDAQ: LEXX) and its patented DehydraTECH(TM) delivery
platform. Suitable for use across a wide range of product
formats such as pharmaceuticals, nutraceuticals and
over-the-counter products, Lexaria’s DehydraTECH also increases the
delivery characteristics of orally administered nicotine.
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM),
improves the way active pharmaceutical ingredients (“APIs”) enter
the bloodstream by promoting more effective oral delivery. Since
2016, DehydraTECH has repeatedly demonstrated the ability to
increase bioabsorption with cannabinoids and nicotine by up to five
to ten times, reduce time of onset from one to two hours to
minutes, and mask unwanted tastes; the innovative tech is also
being evaluated for orally administered anti-viral drugs,
nonsteroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors
and more. DehydraTECH has also evidenced an ability to deliver some
drugs more effectively across the blood brain barrier. Lexaria
operates a licensed in-house research laboratory and holds a robust
intellectual property portfolio with 25 patents granted and more
than 50 patents pending worldwide.
For more information about the company, visit
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and
updates relating to LEXX are available in the company’s newsroom
at https://ibn.fm/LEXX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers,
(2) NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness.
NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS”
to 77948 (U.S. Mobile Phones Only)For more information please
visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or
re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Apr 2023 to Apr 2024